World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.
The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.
Boers
M
M
Department of Internal Medicine/Rheumatology, University Hospital Maastricht, The Netherlands.
Tugwell
P
P
Felson
D T
DT
van Riel
P L
PL
Kirwan
J R
JR
Edmonds
J P
JP
Smolen
J S
JS
Khaltaev
N
N
Muirden
K D
KD
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D012219:Rheumatology; D012720:Severity of Illness Index; D012955:Societies, Medical; D016896:Treatment Outcome; D014944:World Health Organization
D018501:Antirheumatic Agents